AptinyxLogo_FullColor_RGB.jpg
Aptinyx Announces Proposed Public Offering of Common Stock
09 janv. 2020 16h08 HE | Aptinyx Inc.
EVANSTON, Ill., Jan. 09, 2020 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous...
AptinyxLogo_FullColor_RGB.jpg
Aptinyx to Present at 38th Annual J.P. Morgan Healthcare Conference
12 déc. 2019 07h07 HE | Aptinyx Inc.
EVANSTON, Ill., Dec. 12, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and...
AptinyxLogo_FullColor_RGB.jpg
Aptinyx Initiates Phase 2 Study of NYX-458 in Patients with Mild Cognitive Impairment Associated with Parkinson’s Disease
05 déc. 2019 06h58 HE | Aptinyx Inc.
Phase 2 study follows NYX-458 preclinical data demonstrating reversal of cognitive deficits in non-human primate model of Parkinson’s disease Fourth Phase 2 study initiated by Aptinyx in 2019 across...
AptinyxLogo_FullColor_RGB.jpg
Aptinyx Announces Results of Phase 2 Fibromyalgia Study of NYX-2925 Have Been Selected for Late-Breaking Presentation at the American College of Rheumatology Annual Meeting
28 oct. 2019 07h57 HE | Aptinyx Inc.
Study met primary and secondary endpoints – statistically significant effects on neuroimaging biomarkers and patient-reported measures ePoster to be presented at ACR Annual Meeting on Tuesday,...
Schall Firm Logo 2.jpg
ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Aptinyx Inc. and Encourages Investors with Losses to Contact the Firm
23 sept. 2019 17h27 HE | Schall Law
LOS ANGELES, Sept. 23, 2019 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Aptinyx Inc....
AptinyxLogo_FullColor_RGB.jpg
Former Principal Deputy Commissioner of FDA, Dr. Rachel Sherman, Joins Aptinyx Board of Directors
04 sept. 2019 07h27 HE | Aptinyx Inc.
EVANSTON, Ill., Sept. 04, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous...
AptinyxLogo_FullColor_RGB.jpg
Aptinyx Presents Data Demonstrating Positive Activity of NYX-458 on Cognitive Performance and Biomarkers in a Preclinical Model of Head Injury
21 août 2019 08h33 HE | Aptinyx Inc.
EVANSTON, Ill., Aug. 21, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous...
AptinyxLogo_FullColor_RGB.jpg
Aptinyx Reports Second Quarter 2019 Financial Results and Highlights
12 août 2019 06h33 HE | Aptinyx Inc.
Reported that NYX-2925 met primary and secondary endpoints in Phase 2 fibromyalgia study On track to initiate three additional Phase 2 studies in 2H 2019 across pipeline of CNS product candidates ...
AptinyxLogo_FullColor_RGB.jpg
Aptinyx to Present at the 2019 Wedbush PacGrow Healthcare Conference
06 août 2019 08h33 HE | Aptinyx Inc.
EVANSTON, Ill., Aug. 06, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous...
AptinyxLogo_FullColor_RGB.jpg
Aptinyx Presents Preclinical Data Demonstrating Robust Activity of NYX-783 on Alcohol-Seeking Behavior and Relapse-Like Behavior in Multiple Models of Alcohol Use Disorder
26 juin 2019 08h03 HE | Aptinyx Inc.
EVANSTON, Ill., June 26, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous...